Table 2.
Pharmacokinetics parameters for the plasma concentrations of paclitaxel (PTX) and everolimus (EVER) after a single intravenous administration of dual-targeted PTX+EVER-loaded nanoparticles (Dual-NPs) versus free PTX+EVER combination to healthy BALB/c female mice.
| Treatment | Cmax (µg/mL) | T1/2z (h) | AUC0–t (µg h mL−1) | AUC0–inf. (µg h mL−1) | CLtot (mL h kg−1) | Vd (mL kg−1) | |
|---|---|---|---|---|---|---|---|
| Free Combination | PTX | 64.91 | 1.88 | 170.49 a | 172.09 | 81.35 | 222.52 |
| EVER | 38.41 | 1.02 | 83.6 b | 84.88 | 88.35 | 131.73 | |
| Dual-NPs | PTX | 458.03 | 5.17 | 3666.65 c | 3671.59 | 3.81 | 28.47 |
| EVER | 351.25 | 3.78 | 1792.52 d | 1814.83 | 4.13 | 22.85 | |
Cmax = the maximum plasma concentration; t1/2z = half-life at the terminal phase; AUC = area under the curve; CLtot = total body clearance; Vd = volume of distribution. a AUC0–12 h, b AUC0–6 h, c AUC0–48 h, d AUC0–24 h. (n = 5).